Resistance to antiangiogenic therapies. - Wikidata - wikimedia - TriplyDB

Resistance to antiangiogenic therapies.

Resistance to antiangiogenic therapies.

http://www.wikidata.org/entity/Q38232852

about

MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation "Fishing" out the real VEGFs.

P2860

Q36840372-D81E8F5B-D193-4DFF-9BA7-8928BA811828 Q47141388-6975EB15-8C16-43DC-9938-6CE8AC5DFDC5

P2860

Resistance to antiangiogenic therapies.

http://www.wikidata.org/entity/Q38232852

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Resistance to antiangiogenic therapies.

@en

type

label

Resistance to antiangiogenic therapies.

@en

prefLabel

Resistance to antiangiogenic therapies.

@en

P1433

Q38232852-92F42BF6-AD34-4EA4-83D6-4EDE8ED1AB22

P1476

Q38232852-06A44E62-0FDB-4FB6-80FE-FD5FA4552412

P2093

Q38232852-64FD5D20-F510-449A-93E8-2B804247E08B

Q38232852-9661B70F-5976-48A7-A3F5-6D56C3317480

Q38232852-A9A45B08-9C45-4A60-8E50-1E88E9F4AC03

Q38232852-C05731A5-B6BF-4E61-992C-5C0505FE691F

Q38232852-EEC2BC3A-5724-49A4-9410-26E5E6EF883D

P2860

Q38232852-01BA29BF-1DC6-4440-A287-2E041FD0E525

Q38232852-05287095-EB11-43E7-A317-7E8B01E79CCC

Q38232852-0DD46267-632C-4781-ACFD-03BC3E7D5D02

Q38232852-1A6D27CD-5E0F-4CED-9AE0-2AF695115015

Q38232852-1CCD8095-72CD-4A88-B8C7-AE21475C5C1A

Q38232852-1E852B6F-F453-4036-8A74-27677F80B19C

Q38232852-229FAD82-ED5A-4EFD-BF9A-7AB313E6E108

Q38232852-262E11C7-BA0B-422B-8400-9CC8633310B1

Q38232852-2ACD61B8-346F-4174-8413-28B79B3697B1

Q38232852-2CA9B563-169D-48C3-80AB-19EA6AB0F232

P304

Q38232852-F17E05C8-425F-42FC-9FD5-E642914D6514

P31

Q38232852-13F032F6-F986-431F-887B-DF5661C2B7D4

P356

Q38232852-B8F23F1A-3FA0-40C6-972D-E28636640DBD

P407

Q38232852-56AD0F5C-EA5B-40C2-AD67-88929D26B58D

P433

Q38232852-90CA039D-3CCA-41FE-BB00-C19C4FA9A609

P478

Q38232852-3C8C37BA-35CE-4E1B-9E00-31C684CBB2C4

P50

Q38232852-62C51616-4453-43C2-A018-9C8D8A4CB89E

P577

Q38232852-02F350FE-9BBF-4EDA-B4EF-1C63BC793728

P698

Q38232852-1D30A18B-2533-4B8D-855C-6E5C981ED119

P356

P1433

Future Oncology

P1476

Resistance to antiangiogenic therapies.

@en

P2093

Alba A Brandes

http://www.w3.org/2001/XMLSchema#string

Alicia Tosoni

http://www.w3.org/2001/XMLSchema#string

Marco Bartolotti

http://www.w3.org/2001/XMLSchema#string

Monica Di Battista

http://www.w3.org/2001/XMLSchema#string

Rosalba Poggi

http://www.w3.org/2001/XMLSchema#string

P2860

PI3K/AKT/mTOR Pathway in Angiogenesis

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Sorafenib in advanced hepatocellular carcinoma

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Sorafenib in advanced clear-cell renal-cell carcinoma

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

The STATs of cancer--new molecular targets come of age

P304

1417-1425

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.14.57

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Enrico Franceschi

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25052752

http://www.w3.org/2001/XMLSchema#string